In this study, we confirmed the applicability of the CytoDisc for retracing of CTCs, and studies are ongoing in our group to develop downstream analysis of existing cancer biomarkers, such as HER2 in breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.